Faeth Therapeutics (FTH) Accumulated Expenses (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Accumulated Expenses came in at $4.2 million in Q1 2026, up 118.39% YoY from $1.9 million in Q1 2025, and up 8238.0% on a QoQ basis from $50000.0 in Q4 2025.
Faeth Therapeutics (FTH) Accumulated Expenses (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Accumulated Expenses data on file, last reported at $4.2 million in Q1 2026.
- Quarterly Accumulated Expenses rose 118.39% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (up 118.39% YoY) and the FY2025 annual result came in at $50000.0, down 96.37% from the prior year.
- Accumulated Expenses improved to $4.2 million in Q1 2026, from $50000.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $4.2 million in Q1 2026 to a low of $40000.0 in Q2 2025.
- A 5-year average of $1.2 million and a median of $1.0 million in 2022 frame the typical range for Accumulated Expenses.
- The widest YoY moves for Accumulated Expenses: up 271.4% in 2025, down 96.37% in 2025.
- Tracing FTH's Accumulated Expenses over 5 years: stood at $2.5 million in 2022, then slumped by 41.31% to $1.4 million in 2023, then slipped by 4.57% to $1.4 million in 2024, then slumped by 96.37% to $50000.0 in 2025, then surged by 8238.0% to $4.2 million in 2026.
- The last three Accumulated Expenses figures came in at $4.2 million (Q1 2026), $50000.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Faeth Therapeutics | 179.31 Mn | 179.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.25 Mn |
| Mar 31, 2026 | 4.17 Mn |
| Dec 31, 2025 | 50,000.00 |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 40,000.00 |
| Mar 31, 2025 | 1.91 Mn |
| Dec 31, 2024 | 1.38 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 848,000.00 |
| Mar 31, 2024 | 514,000.00 |
| Dec 31, 2023 | 1.45 Mn |
| Sep 30, 2023 | 1.09 Mn |
| Jun 30, 2023 | 715,000.00 |
| Mar 31, 2023 | 583,000.00 |
| Dec 31, 2022 | 2.46 Mn |
| Sep 30, 2022 | 1.76 Mn |
| Jun 30, 2022 | 1.02 Mn |
| Mar 31, 2022 | 560,000.00 |
| Dec 31, 2021 | 1.75 Mn |
| Sep 30, 2021 | 1.62 Mn |